At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 7 enrolled
Drug / intervention
Ertapenemdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacokinetics and Investigation of Optimal Dose of Invanz (Ertapenem) in Hemodialysis Patients
In Brief
A Phase 2 clinical trial evaluating Ertapenem for End Stage Renal Disease. Completed, enrolled 7 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the amount of ertapenem in the blood over time between hemodialysis session.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd Stage Renal Disease
CountriesUnited States
CollaboratorsWayne State University
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartDec 2014
Primary CompletionApr 2016
TodayJul 2026
First PostedJun 10, 2014
Enrollment StartDec 1, 2014
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.1 years ago
Interventions
Ertapenemdrug
Subjects are hemodialysis patients who are admitted to Oakwood Hospital - Dearborn